Figure 3.

Change in JAK2-V617F allele burden and molecular response. (A) Median JAK2 V617F allele burden (JAK2) with 95% confidence interval (95% CI), using a generalized linear mixed model to compare baseline with time points during treatment. (B) Waterfall plot over the best relative reduction in JAK2 with an indication of complete molecular response (CMR), partial molecular response (PMR), and no molecular response (NMR) with baseline value below or above 20%. (C) Median JAK2 and 95% CI in patients in partial or complete remission after 24 months and patients not in remission with stars representing a statistically significant difference in change from baseline between groups. (D) Cumulative incidence of peripheral blood cell remission (PBCR) in patients achieving a molecular response after 2 years and patients not achieving a molecular response. *P<0.05; **P<0.01; ***P<0.001